Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571261 | 0.84 | USP2 (0.43) | LRRK2PTGDR2KDM4EPOLBPKM | |
| SCHEMBL15880288 | 0.75 | HTT (0.51) | NAPRTKDM4EMAPTMEN1KMT2A | |
| SCHEMBL22319389 | 0.75 | PTGER4 (0.49) | KDM4EGLAPOLBMAPTKMT2A | |
| SCHEMBL31028181 | 0.75 | PTGER4 (0.49) | KDM4EGLAPOLBMAPTKMT2A | |
| SCHEMBL2371565 | 0.72 | POLB (0.49) | PTGDR2KDM4EGLAPOLBMAPT | |
| SCHEMBL19305655 | 0.72 | KDM4E (0.55) | PTGDR2KDM4EGLAPOLBMAPT | |
| SCHEMBL2371418 | 0.72 | KDM4E (0.41) | SORT1KDM4EGLA | |
| SCHEMBL2372193 | 0.71 | KDM4E (0.42) | PTGDR2KDM4EGLAPOLBMEN1 | |
| SCHEMBL26936307 | 0.71 | KDM4E (0.67) | SORT1PTGDR2KDM4EGLAPOLB | |
| SCHEMBL2779965 | 0.70 | ROCK2 (0.46) | SORT1KDM4EPOLBMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346827-B2 | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-8962859-B2 | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8921363-B2 | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors | AMGEN INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2601197-B1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2328903-B1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140038954-A1 | Spiro-Amino-Imidazo-Fused Heterocyclic Compounds as Beta-secretase Modulators and Methods of Use | AMGEN INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140031340-A1 | 5-Amino-Oxazepine and 5-Amino-Thiazepane Compounds as Beta Secretase Antagonists and Methods of Use | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2675810-A1 | SPIRO-AMINO-IMIDAZO-FUSED HETEROCYCLIC COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2012112462-A1 | SPIRO-AMINO-IMIDAZO-FUSED HETEROCYCLIC COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012109165-A1 | 5-AMINO-OXAZEPINE AND 5-AMINO-THIAZEPANE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012071279-A1 | SPIRO-AMINO-IMIDAZOLONE AND SPIRO-AMINO-DIHYDRO-PYRIMIDINONE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012019056-A1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| EP-2328903-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031340-A1 | 5-Amino-Oxazepine and 5-Amino-Thiazepane Compounds as Beta Secretase Antagonists and Methods of Use | BACE1, BACE2, APP | NAPRT 2689/4885SORT1 2193/4885LRRK2 667/4885 |
| US-20140038954-A1 | Spiro-Amino-Imidazo-Fused Heterocyclic Compounds as Beta-secretase Modulators and Methods of Use | BACE1, BACE2, APP | NAPRT 2303/4885SORT1 1699/4885LRRK2 70/4885 |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | NAPRT 2630/4885SORT1 1245/4885LRRK2 155/4885 |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | NAPRT 2373/4885SORT1 1884/4885LRRK2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.